1. Home
  2. AUUD vs ENTO Comparison

AUUD vs ENTO Comparison

Compare AUUD & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUUD
  • ENTO
  • Stock Information
  • Founded
  • AUUD 2012
  • ENTO 2014
  • Country
  • AUUD United States
  • ENTO United States
  • Employees
  • AUUD N/A
  • ENTO N/A
  • Industry
  • AUUD Computer Software: Prepackaged Software
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • AUUD Technology
  • ENTO Health Care
  • Exchange
  • AUUD Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • AUUD 2.9M
  • ENTO 2.5M
  • IPO Year
  • AUUD 2021
  • ENTO 2016
  • Fundamental
  • Price
  • AUUD $4.32
  • ENTO $0.41
  • Analyst Decision
  • AUUD
  • ENTO
  • Analyst Count
  • AUUD 0
  • ENTO 0
  • Target Price
  • AUUD N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • AUUD 36.7K
  • ENTO 98.4K
  • Earning Date
  • AUUD 03-05-2025
  • ENTO 05-20-2025
  • Dividend Yield
  • AUUD N/A
  • ENTO N/A
  • EPS Growth
  • AUUD N/A
  • ENTO N/A
  • EPS
  • AUUD N/A
  • ENTO N/A
  • Revenue
  • AUUD N/A
  • ENTO N/A
  • Revenue This Year
  • AUUD N/A
  • ENTO N/A
  • Revenue Next Year
  • AUUD N/A
  • ENTO N/A
  • P/E Ratio
  • AUUD N/A
  • ENTO N/A
  • Revenue Growth
  • AUUD N/A
  • ENTO N/A
  • 52 Week Low
  • AUUD $3.35
  • ENTO $0.19
  • 52 Week High
  • AUUD $96.90
  • ENTO $4.23
  • Technical
  • Relative Strength Index (RSI)
  • AUUD 40.49
  • ENTO 37.79
  • Support Level
  • AUUD $3.35
  • ENTO $0.39
  • Resistance Level
  • AUUD $6.19
  • ENTO $0.61
  • Average True Range (ATR)
  • AUUD 0.57
  • ENTO 0.07
  • MACD
  • AUUD -0.04
  • ENTO -0.01
  • Stochastic Oscillator
  • AUUD 34.18
  • ENTO 8.93

About AUUD Auddia Inc.

Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: